Recent Insider Transactions • Jun 18
Senior VP recently sold US$72k worth of stock On the 16th of June, Jeffrey Cerio sold around 7k shares on-market at roughly US$10.83 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. In the last 3 months, there was an even bigger sale from another insider worth US$197k. Insiders have been net sellers, collectively disposing of US$376k more than they bought in the last 12 months. Recent Insider Transactions Derivative • Jun 17
Senior VP notifies of intention to sell stock Jeffrey Cerio intends to sell 7k shares in the next 90 days after lodging an Intent To Sell Form on the 16th of June. If the sale is conducted around the recent share price of US$10.83, it would amount to US$72k. As of today, Jeffrey currently holds no shares directly (This sale likely refers to shares that have not yet been received). There has only been one transaction (US$197k sale) from insiders over the last 12 months. New Risk • Jun 10
New minor risk - Insider selling There has been significant insider selling in the company's shares over the past 3 months. Total value of shares sold: US$197k This is considered a minor risk. There are several reasons why an insider may be selling, including to cover a tax obligation or pay for some other expense. However, we generally consider it a negative if insiders have been selling, especially if they do so below the current price. It implies that they considered a lower price to be reasonable. This is a weak signal, but if there is a pattern of unexplained selling, it can be a sign the insider believes the company's stock is overpriced. Note: We only include open market transactions and private dispositions of directly owned stock by individuals, not by corporations or trusts. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 12% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$123m net loss in 3 years). Share price has been volatile over the past 3 months (12% average weekly change). Significant insider selling over the past 3 months (US$197k sold). Revenue is less than US$5m (US$3.8m revenue). Recent Insider Transactions • Jun 02
CEO, President recently sold US$197k worth of stock On the 29th of May, Ram Aiyar sold around 15k shares on-market at roughly US$12.98 per share. This transaction amounted to 16% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was Ram's only on-market trade for the last 12 months. Recent Insider Transactions Derivative • May 31
CEO, President notifies of intention to sell stock Ram Aiyar intends to sell 15k shares in the next 90 days after lodging an Intent To Sell Form on the 29th of May. If the sale is conducted around the recent share price of US$12.98, it would amount to US$197k. For the year to December 2022, Ram's total compensation was 20% salary and 80% other compensation. This indicates that these sales could comprise a meaningful part of their income for the year. Since March 2026, Ram has owned 4.61k shares directly. There have been no trades via on-market transactions or options from company insiders in the last 12 months. Major Estimate Revision • May 21
Consensus revenue estimates increase by 11%, EPS downgraded The consensus outlook for fiscal year 2026 has been updated. 2026 revenue forecast increased from US$500.0k to US$560.0k. EPS estimate fell from -US$5.27 to -US$5.45 per share. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target down from US$20.38 to US$19.89. Share price was steady at US$11.20 over the past week. Aankondiging • May 20
Korro Bio, Inc. Selects Krro-111 As Development Candidate For The Potential Treatment Of Alpha-1 Antitrypsin Deficiency Korro Bio, Inc. announced the addition of KRRO-111 for the potential treatment of AATD to its pipeline of therapeutic programs in development. KRRO-111 is a proprietary GalNAc-conjugated oligonucleotide that is delivered subcutaneously to the liver cells, where it is engineered to co-opt the hepatocytes’ endogenous Adenosine Deaminase Acting on RNA (ADAR) enzyme and repair a pathogenic single nucleotide variant (SNV) on AAT mRNA to restore production of normal AAT protein. This therapeutic profile along with KRRO-111’s rapid onset of action and titratable dosing to treat this disorder, position the compound as a potential best-in-class candidate. AATD is a genetic disorder most commonly caused by a single missense mutation (G-to-A) in the SERPINA1 gene. Affected adults experience pulmonary emphysema and/or hepatic cirrhosis, as well as end organ manifestations. Greater than 95% of severe clinical cases of AATD are homozygous for the PiZ mutation (known as the PiZZ genotype). There are an estimated 3,400,000 individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived AAT protein, which does not adequately address the manifestations of AATD. In preclinical studies, KRRO-111 demonstrated best-in-class RNA editing where >90% of the AAT transcripts in the liver cells have been corrected, translating into ~90% M-AAT protein. In a repeat-dose study, KRRO-111 (3 mg/kg) was administered to PiZZ mice with a loading phase followed by dosing once every two weeks. KRRO-111 nearly eliminated active Z protein production, reducing non-inclusion Z-AAT by ~95% versus vehicle at both days 28 and 56, reflecting near-complete cessation of Z protein synthesis across the hepatocyte population. Pre-existing aggregates were progressively cleared, with inclusion-associated Z-AAT significantly reduced by approximately 69% at day 28, consistent with autophagic clearance of accumulated protein following successful editing; the residual burden reflects pre-existing disease rather than incomplete editing. By simultaneously increasing circulating M-AAT protein and decreasing pathogenic Z-AAT aggregates in the lung, KRRO-111 has the potential to improve both lung and liver manifestations of the disease. The Company plans to present additional data from its KRRO-111 program at a future scientific meeting or Company-hosted event. Major Estimate Revision • May 14
Consensus EPS estimates upgraded to US$5.27 loss The consensus outlook for fiscal year 2026 has been updated. 2026 losses forecast to reduce from -US$6.75 to -US$5.27 per share. Revenue forecast unchanged from US$500.0k at last update. Biotechs industry in the US expected to see average net income decline 9.8% next year. Consensus price target of US$20.38 unchanged from last update. Share price fell 16% to US$11.20 over the past week. Reported Earnings • May 07
First quarter 2026 earnings released: US$1.69 loss per share (vs US$2.49 loss in 1Q 2025) First quarter 2026 results: US$1.69 loss per share (improved from US$2.49 loss in 1Q 2025). Net loss: US$19.6m (loss narrowed 16% from 1Q 2025). Revenue is forecast to grow 60% p.a. on average during the next 3 years, compared to a 21% growth forecast for the Biotechs industry in the US. Aankondiging • Apr 17
Korro Bio, Inc., Annual General Meeting, Jun 10, 2026 Korro Bio, Inc., Annual General Meeting, Jun 10, 2026. Major Estimate Revision • Mar 19
Consensus revenue estimates increase by 52,586% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$1.27m to US$667.4m. Forecast losses expected to reduce from -US$8.27 to -US$6.75 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target up from US$19.33 to US$20.00. Share price fell 3.8% to US$11.06 over the past week. New Risk • Mar 13
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 54% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 9.8% per year for the foreseeable future. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$108m net loss in 3 years). Aankondiging • Mar 09
Korro Bio, Inc. announced that it expects to receive $84.996839 million in funding from a group of investors Korro Bio, Inc announced a private placement and entered into a subscription agreement to issue 4,501,928 common shares at price of $11.11 per share for aggregate proceeds of $50,016,420.08 and 3,148,836 pre-funded warrants at a price of $11.109 for aggregate proceeds of $34,980,419.124, total gross proceeds amounting to $84,996,839.204 on March 9. 2026. The transaction included participation from lead Investor Venrock Healthcare Capital Partners, ADAR1 Capital Management, Affinity Asset Advisors, Balyasny Asset Management, Driehaus Capital Management, Kalehua Capital, Lynx1 Capital Management, Nantahala Capital, and New Enterprise Associates. The pre-funded warrants have an exercise price of $0.001 per underlying share of common stock, are immediately exercisable and have no expiration date. The transaction is expected to close on March 10, 2026 subject to customary closing conditions. The securities will be issued in reliance upon the exemption from securities registration afforded by Section 4(a)(2) of the 1933 Act and not in reliance upon any of the safe harbors set forth in Regulation D promulgated thereunder. Price Target Changed • Feb 12
Price target increased by 123% to US$19.33 Up from US$8.67, the current price target is an average from 6 analysts. New target price is 64% above last closing price of US$11.76. Stock is down 60% over the past year. The company is forecast to post a net loss per share of US$9.05 next year compared to a net loss per share of US$9.37 last year. Board Change • Feb 12
High number of new and inexperienced directors There are 12 new directors who have joined the board in the last 3 years. The company's board is composed of: 12 new directors. No experienced directors. No highly experienced directors. Independent Director Ali Behbahani is the most experienced director on the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • Oct 08
Korro Bio, Inc. Announces Chief Financial Officer Changes, Effective October 17, 2025 On October 7, 2025, Vineet Agarwal announced his intention to resign from his position of Chief Financial Officer of Korro Bio, Inc., or Korro, effective October 17, 2025 to pursue another opportunity. In order to ensure the smooth transition of his functions, Mr. Agarwal has agreed to be available to serve as an advisor for 30 days thereafter. The board of directors of Korro, or the Board, and Korro are incredibly thankful to Mr. Agarwal for his long-standing service at Korro. In light of Mr. Agarwal’s resignation, the Board appointed Dr. Ram Aiyar, President and Chief Executive Officer (principal executive officer), to serve as Korro’s interim Chief Financial Officer and principal financial officer, in addition to his current duties effective from October 17, 2025. Price Target Changed • Sep 10
Price target decreased by 8.4% to US$92.33 Down from US$101, the current price target is an average from 9 analysts. New target price is 156% above last closing price of US$36.12. Stock is down 7.0% over the past year. The company is forecast to post a net loss per share of US$10.14 next year compared to a net loss per share of US$9.37 last year. Major Estimate Revision • Aug 19
Consensus revenue estimates increase by 47%, EPS downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$3.31m to US$4.85m. EPS estimate fell from -US$9.55 to -US$10.14 per share. Biotechs industry in the US expected to see average net income decline 12% next year. Consensus price target broadly unchanged at US$99.23. Share price rose 20% to US$19.14 over the past week. New Risk • Jun 06
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 17% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings are forecast to decline by an average of 9.1% per year for the foreseeable future. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$146m net loss in 3 years). Revenue is less than US$5m (US$4.8m revenue). Price Target Changed • May 16
Price target decreased by 13% to US$102 Down from US$117, the current price target is an average from 10 analysts. New target price is 574% above last closing price of US$15.11. Stock is down 72% over the past year. The company is forecast to post a net loss per share of US$9.55 next year compared to a net loss per share of US$9.37 last year. Major Estimate Revision • May 14
Consensus revenue estimates increase by 137% The consensus outlook for revenues in fiscal year 2025 has improved. 2025 revenue forecast increased from US$1.35m to US$3.20m. Forecast losses expected to reduce from -US$10.23 to -US$9.51 per share. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$117 to US$102. Share price was steady at US$14.11 over the past week. Aankondiging • Apr 30
Korro Bio, Inc., Annual General Meeting, Jun 11, 2025 Korro Bio, Inc., Annual General Meeting, Jun 11, 2025. Price Target Changed • Apr 29
Price target decreased by 7.3% to US$117 Down from US$126, the current price target is an average from 10 analysts. New target price is 601% above last closing price of US$16.67. Stock is down 71% over the past year. The company is forecast to post a net loss per share of US$10.23 next year compared to a net loss per share of US$9.37 last year. Major Estimate Revision • Apr 24
Consensus revenue estimates increase by 156% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from US$250.0k to US$640.0k. EPS estimate unchanged from -US$10.40 at last update. Biotechs industry in the US expected to see average net income decline 13% next year. Consensus price target down from US$139 to US$122. Share price rose 25% to US$17.44 over the past week. Price Target Changed • Apr 17
Price target decreased by 9.9% to US$126 Down from US$140, the current price target is an average from 9 analysts. New target price is 807% above last closing price of US$13.90. Stock is down 79% over the past year. The company is forecast to post a net loss per share of US$10.40 next year compared to a net loss per share of US$9.37 last year. Aankondiging • Apr 01
Korro Bio, Inc. Appoints Loïc Vincent as Chief Scientific Officer Korro Bio, Inc. announced the appointment of Loïc Vincent as Chief Scientific Officer. Dr. Vincent joins Korro with more than 20 years in drug discovery and translational research across academia, biotech and the pharmaceutical industry. Throughout his career, Dr. Vincent led teams that advanced more than 20 drugs into clinical development based on various therapeutic modalities including small molecules, biologics, viral platforms and cell therapies. Prior to joining Korro, Dr. Vincent served as Chief Scientific Officer at Affini-T Therapeutics leading efforts to advance next-generation therapies. Previously, he was Head of the Oncology Drug Discovery Unit and Immunology Unit at Takeda. Before that, Dr. Vincent led Oncology Drug Discovery Pharmacology, Immunotherapy and Oncology External Innovation teams at Sanofi, and earlier in his career, he headed Pharmacology and Oncology programs at Endotis Pharma. Dr. Vincent currently serves on the Scientific Advisory Boards of bit.bio and General Inception, and is a Director on the Board of Alaya.bio. Dr. Vincent obtained his Ph.D. in pharmacology from the University of Rouen, France, and completed his postdoctoral fellowship in oncology at the Weill Medical College of Cornell University, New York. Aankondiging • Feb 13
Korro Bio, Inc. Appoints Oliver Dolan as Interim Principal Accounting Officer Effective February 11, 2025, Vineet Agarwal, Chief Financial Officer (principal financial officer and principal accounting officer) of Korro Bio, Inc., is taking a temporary medical leave of absence. Accordingly, effective from February 11, 2025, Korro’s Board of Directors appointed Mr. Oliver Dolan, Senior Vice President, Finance, to serve as Korro’s interim principal accounting officer, in each case, in addition to their current duties. Mr. Dolan, age 42, has served as Korro’s Senior Vice President of Finance since January 2024. Prior to joining Korro, Mr. Dolan served as Vice President, Accounting, Tax and Treasury at Unity Biotechnology from December 2020 to December 2023. Prior to that, Mr. Dolan served as Head of Finance at Haven Healthcare from May 2020 to December 2020. Prior to that, Mr. Dolan served as Vice President of Finance at Compass Therapeutics from October 2018 to May 2020. Mr. Dolan holds an MBA from MIT Sloan School of Management, a Bachelor of Commerce degree from the University College Dublin and he is licensed as a Certified Public Accountant. Aankondiging • Jan 13
Korro Bio Announces Dosing of First Participants in REWRITE Phase 1/2a Study of KRRO-110 for Alpha-1 Antitrypsin Deficiency Korro Bio, Inc. announced the initiation of dosing in its REWRITE study investigating KRRO-110 as a potential treatment for individuals with Alpha-1 Antitrypsin Deficiency (AATD). REWRITE is a two-part single and multiple dose-escalating study that will evaluate the safety and tolerability of KRRO-110 in up to 64 participants, including healthy adults and clinically stable AATD patients with the PiZZ genotype. Secondary and exploratory endpoints include pharmacokinetic and pharmacodynamic parameters that will guide optimal dose selection for later stage studies. Interim data from Part 1 (single ascending doses in healthy volunteers and individuals with AATD) is expected in the second half of 2025, and completion of the study is anticipated in 2026. For additional information about the REWRITE study, visit ClinicalTrials.gov (NCT06677307). In addition to advancing KRRO-110, Korro is progressing a pipeline of wholly owned programs and a Novo Nordisk partnered program in a cardiometabolic indication towards the clinic. Aankondiging • Dec 03
Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million. Korro Bio, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.
Security Name: Common Stock
Security Type: Common Stock
Transaction Features: At the Market Offering Recent Insider Transactions Derivative • Nov 17
Chief Financial Officer notifies of intention to sell stock Vineet Agarwal intends to sell 800 shares in the next 90 days after lodging an Intent To Sell Form on the 11th of November. If the sale is conducted around the recent share price of US$70.00, it would amount to US$56k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$767k more than they bought, via options and on-market transactions in the last 12 months. Recent Insider Transactions Derivative • Oct 20
Chief Financial Officer notifies of intention to sell stock Vineet Agarwal intends to sell 10k shares in the next 90 days after lodging an Intent To Sell Form on the 17th of October. If the sale is conducted around the recent share price of US$78.26, it would amount to US$800k. Since December 2023, Vineet has not owned shares directly (This sale likely refers to shares that have not yet been received). Company insiders have collectively sold US$761k more than they bought, via options and on-market transactions in the last 12 months. Aankondiging • Aug 28
Korro Bio, Inc. Announces Board Changes Korro Bio, Inc. announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage development to regulatory approval and commercialization. She most recently served as Chief Medical Officer at Agilent Technologies, where she established an industry-leading medical affairs organization and was responsible for integrating the voice of patients into business and clinical development strategy and decision-making. Previously, she was Chief Medical Officer and Head of Research and Development at Kaleido Biosciences. Before that, Dr. Knobil spent more than 20 years at GlaxoSmithKline (GSK) in roles of increasing responsibility, most recently serving as Chief Medical Officer. Dr. Knobil is currently a member of the Board of Directors at Nimbus Therapeutics, Marker Therapeutics and Pliant Therapeutics. Dr. Knobil is a recognized leader in the field, having authored numerous publications and presented at major industry conferences. She received an M.D. from the University of Texas Southwestern Medical School and completed her subsequent fellowship in Pulmonary Medicine and Critical Care Medicine at Johns Hopkins University. Board Change • May 17
High number of new and inexperienced directors There are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. No experienced directors. 1 highly experienced director. Director David Lucchino is the most experienced director on the board, commencing their role in 2014. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Aankondiging • May 16
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer Korro Bio, Inc. announced the appointment of Dr. Kemi Olugemo as Chief Medical Officer. Dr. Olugemo brings more than 10 years of industry experience focused on clinical development and regulatory strategy. She joins Korro after serving as VP & Therapeutic Head, Neurology Global Clinical Development at Ultragenyx Pharmaceutical. In this role, she directed and oversaw the overall strategy for clinical drug product development, supported the development of global regulatory plans, and identified critical opportunities for external collaborations. Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and a B.Sc. in Clinical Laboratory Science from the University of Massachusetts, Lowell. With her experience in rare and more prevalent diseases, Dr. Olugemo will provide invaluable expertise and leadership to advance Korro’s clinical and regulatory initiatives. Aankondiging • May 01
Korro Bio, Inc., Annual General Meeting, Jun 11, 2024 Korro Bio, Inc., Annual General Meeting, Jun 11, 2024, at 13:30 US Eastern Standard Time. Agenda: To consider Election of two Class II directors, Ali Behbahani and Timothy Pearson, nominated by board of directors, each to serve for a three-year term expiring at the 2027 annual meeting of stockholders; to consider Approval of an amendment to Restated Certificate of Incorporation to limit the liability of certain officers as permitted by amendments to Delaware law; to consider Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to consider other matters. Aankondiging • Apr 23
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc. On April 22, 2024, Korro Bio, Inc. closed the transaction. Aankondiging • Apr 19
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc. Korro Bio, Inc. announces it has entered into a subscription agreement with a number of institutional accredited investors to issue 1,249,283 shares of common stock at a issue price of $56 per share for gross proceeds of $69,959,848 on April 17, 2024. The transaction will include participation from Deep Track Capital, as lead investor and Atlas Venture, Blue Owl Healthcare Opportunities, NEA, Rock Springs Capital, Tri Locum Partners, and other leading healthcare investors. The transaction is expected to close on April 22, 2024. New Risk • Dec 08
New minor risk - Financial data availability Less than 3 years of financial data is available. This is considered a minor risk. If the company has been trading for less than 3 years, then it has not had the opportunity to establish a long-term track record. This makes it difficult for investors to assess the true growth potential, sustainability and resilience of the business under different economic conditions. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings are forecast to decline by an average of 8.4% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Less than 3 years of financial data is available. Currently unprofitable and not forecast to become profitable over next 3 years (US$93m net loss in 3 years). Significant insider selling over the past 3 months (US$84k sold). Aankondiging • Dec 07
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency Korro Bio, Inc. has nominated its first development candidate, KRRO-110, for the potential treatment of AATD. KRRO-110 is a proprietary RNA editing oligonucleotide delivered to liver cells using clinically validated LNP technology licensed from Genevant. KRRO-110 is designed to co-opt an endogenous enzyme Adenosine Deaminase Acting on RNA (ADAR) to repair a pathogenic single nucleotide variant (SNV) on RNA and restore production of normal A1AT. AATD is an inherited genetic disorder caused by SNVs in the SERPINA1 gene that can lead to severe progressive lung disease, including emphysema and chronic obstructive pulmonary disease (COPD), and liver disease. There are an estimated 3.4 million individuals with deficiency allele combinations worldwide. The only current FDA-approved treatment for AATD is augmentation therapy, a once-weekly infusion of pooled human plasma-derived A1AT protein, which does not adequately address the manifestations of AATD. Aankondiging • Nov 30
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee Korro Bio, Inc. announced the appointment of Rachel Meyers, PhD, to the company’s board of directors. Dr. Meyers is a seasoned biotechnology veteran whose experience in life sciences spans over two decades. Most recently, Dr. Meyers served as Chief Scientific Officer of Faze Medicines. Previously, she was an Entrepreneur-in-Residence at Third Rock Ventures. Before that, Dr. Meyers held multiple leadership positions at Alnylam Pharmaceuticals for over 13 years, most recently as Senior Vice President of Research and RNAi Lead Development. Rachel completed her post-doctoral training at Harvard University and holds a PhD in Biology from the Massachusetts Institute of Technology and a BA in Biochemistry from Brandeis University. Dr. Meyers was also appointed by the Board upon the recommendation of the NCG Committee to serve as a member of the Nominating and Corporate Governance Committee or NCG Committee. Board Change • Nov 07
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Director Omar Khwaja was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Aankondiging • Nov 07
Frequency Therapeutics, Inc. announced that it has received $117.249989 million in funding from a group of investors On November 6, 2023, Frequency Therapeutics, Inc. closed the transaction. The company issued 42,176,255 common shares at a price of $2.78 per share for gross proceeds of $117.249989 million.